Thanks for the comments, longfellow. I'm not trying to time the market -- who can. At some point the FDA and the company will able to disclose the status of the trial, and if the trial is in good stead the share price should reflate, even with the need to raise additional capital. If, as Smith says, there's a deficiency, who knows, as the data may provide directionality.
As another poster helpfully asked, "who cares." Most -- not much. However, the company needs to attract new investors and new capital, and I'm sharing my own experiences in moving from reticence and indifference to making one set, and possibly a successive set.
At this point, whether AF is receiving benefit from the short community, he faces significant career risk if NWBO is successful; his "journalistic" career, as it is at $1/a share thestreet, would never recover given his historical and bizarre commentary and behaviors.
The antidote is information -- and it's not realistic to believe that a new investor will not try to piece the entire picture. While there remains high levels of prickliness on specifically what one calls the status of the trial -- and I'll refer to other posters and Smith on the most appropriate terminology for it -- the entry bet here is that the status of the trial, when clarified will either create a significant loss or a much more significant gain.
Anyway, I just wanted to share with some others who might be considering an entry investment that I waded in and I will continue to purchase shares if/as there are continued rounds. With the optionality of combo trials, the risk reward is compelling.
I am learning that there is a dark cloud of some paranoia that commentary -- even someone who is opening a position -- is out to harm the company and it's shareholders. Most readers of this board will understand what I am communicating and why, but there are clearly a minority who won't and it's not worth the time to wade through the environment.
I may comment in the future and I wanted to sufficiently introduce myself so that questions might be met with less skepticism. In general, though, I will go back to appreciating the comment and work of others on this board, without whom I never would or could have evolved to develop sufficient confidence to start, and continue, a sequence of share purchases.
Market Data 
Markets 
AI
